19 August 2025 in Discover Health Systems
Background and aim: Artificial intelligence has emerged as a transformative tool in healthcare, enhancing diagnostic accuracy, advancing genetic studies, and improving personalized medicine by reducing human error. However, its integration also raises ethical concerns such as potential bias, privacy issues, and uncertainties over decision-making authority. This study aims to evaluate the attitudes and concerns of physicians regarding the use of AI in healthcare, and to explore how these perceptions may impact its implementation in clinical practice. Subject and methods: A nation-wide cross-sectional study was conducted using an online questionnaire, based on standardized General Attitude Towards Artificial Intelligence Scale (GAAIS) and self-devised questions, aimed at collecting data about demographic details, attitude and fears of the physicians regarding AI. Using the convenience sampling technique, a sample of 393 physicians was selected. Independent-samples t-tests, one-way ANOVA, and multiple linear regression were used to analyze differences between variables. Results: The overall attitude on positive subscale of GAAIS was above neutral (mean = 3.46; SD = 0.59) with men showing a significantly better attitude than women on this subscale (MD = 0.22; CI 0.10–0.33; P = < 0.001), while the attitude on negative subscale of GAAIS was slightly below neutral (mean = 2.76; SD = 0.61). Some degree of fear regarding AI was also observed among physicians (mean = 2.66; SD = 0.67). Conclusion: Physicians have mixed views on AI, with concerns over ethical issues associated with it but not fearing replacement by it in near future. Men have a more positive attitude towards it. Integrating AI-focused curricula into medical education, along with conducting longitudinal and prospective studies, is essential to address physicians’ concerns and fully understand AI’s clinical impact.
14 March 2025 in Research Square
Objectives Ventricular tachycardia (VT) in ischemic heart disease (IHD) carries a high risk of sudden cardiac death. Treatment typically involves catheter ablation or antiarrhythmic drugs (AADs), but the optimal approach is uncertain. This meta-analysis compared the safety of these treatments for VT in IHD patients. Methods This meta-analysis included all studies comparing catheter ablation with AADs in IHD patients with symptomatic VT. Databases searched included PubMed, Google Scholar, Embase, and Cochrane Library up to June 9, 2024. Primary outcomes analyzed were recurrent VT, mortality, and heart failure; secondary outcomes included hospitalizations for VT, VT storm, and appropriate anti-tachycardia pacing (AATP). Risk ratios (RR) with 95% confidence intervals (CI) were calculated using a random-effects model. Quality and bias were assessed using the Cochrane ROB 2 tool, and heterogeneity with Higgins I² statistic. Results Three studies with 430 participants were included. No significant difference was found between ablation and AADs for recurrent VT (RR = 1.08; 95%CI = 0.70–1.65; p = 0.74; I²=0%), mortality (RR = 0.98; 95%CI = 0.67–1.42; p = 0.90; I²=0%), and AATP (RR = 1.00; 95%CI = 0.84–1.20; p = 0.97; I²=0%).Heart failure (RR = 0.75; 95%CI = 0.50–1.11; p = 0.15; I²=0%), VT storm (RR = 0.77; 95%CI = 0.55–1.09; p = 0.14; I²=0%), and hospitalizations for VT (RR = 0.59; 95% CI = 0.30–1.15; p = 0.12; I²=62%) were lower with ablation but not significantly. Conclusion While no significant differences emerged, ablation showed a trend toward reducing heart failure and hospitalizations, suggesting potential advantages in managing VT-related complications in IHD. Further large-scale studies are needed to confirm these benefits.
16 August 2026 in Brain and Behavior
Introduction: Alzheimer's disease (AD) is a progressive neurodegenerative disorder with limited treatment options. Gantenerumab, a β‐amyloid–targeting monoclonal antibody, has shown mixed clinical results. With new trial data available, this updated systematic review and meta‐analysis re‐evaluates its efficacy and safety in early AD. Methods: Registered on PROSPERO (CRD420251082463) under PRISMA guidelines, we searched PubMed, Cochrane Library, and Google Scholar from inception to October 2025 for randomized trials in early AD comparing gantenerumab with placebo. A random‐effects model assessed pooled outcomes with heterogeneity ( I 2 ) and sensitivity analyses. Additionally, meta‐regression and certainty of evidence using Gradepro were performed. Risk of bias was evaluated using the Cochrane tool. An Institutional Review Committee (IRC) and its Ethical Review Board (ERB) approval was not required. Results: Six trials (3103 participants: 1718 gantenerumab; 1385 placebo) were included. Gantenerumab showed no significant effect on CDR‐SB (MD = −0.07; 95% CI: −0.34–0.20; p = 0.62; I 2 = 16%) but produced small improvements in FAQ (MD = −0.73; 95% CI: −1.30 to −0.17; p = 0.01; I 2 = 0%) and Amyloid‐PET score (MD = −45.67; 95% CI: −88.09 to −3.24; p = 0.03; I 2 = 99%). While significant statistical improvement was seen in the ADAS‐Cog13 score (MD = −0.95; 95% CI: −1.76 to −0.13; p = 0.02; I 2 = 0%), the effect sizes for both FAQ and ADAS‐Cog13 fell below established MCID thresholds. MMSE and ADCS‐ADL showed no significant differences. Safety analysis revealed higher risks of ARIA‐E (RR = 5.51), ARIA‐H (RR = 1.73), and injection site reactions (RR = 2.15), with no differences in other adverse events. Conclusion: Gantenerumab significantly reduces amyloid and statistically improves select functional (FAQ) and cognitive (ADAS‐Cog13) measures in early AD; however, these changes remain below accepted MCID thresholds, indicating a lack of true clinical meaningfulness. Combined with its failure to enhance global cognition and an increased ARIA risk, routine clinical use is not supported.